Selective Serotonin Reuptake Inhibitors (SSRIs)

FDA declines to authorize common antidepressant as COVID treatment

Antidepressants, Brazil, Coronavirus Disease 2019 (COVID-19), Covid-19 Data, FDA, Fluvoxamine, Generics, Selective Serotonin Reuptake Inhibitors (SSRIs), Therapeutics

The U.S. Food and Drug Administration decided not to authorize the antidepressant fluvoxamine to treat COVID-19, saying the data has not shown the drug to be an effective therapeutic for fighting the virus.

SSRI Antidepressants May Be Effective Early Treatments for Covid-19

Antidepressants, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Generics, JAMA, R&D, Selective Serotonin Reuptake Inhibitors (SSRIs), Studies, Symptoms: Coronavirus Disease 2019 (COVID-19)

Researchers at Washington University School of Medicine in St. Louis published the results of a clinical trial evaluating an antidepressant, fluvoxamine, for early treatment for Covid-19.

Pfizer defeats appeals over Zoloft birth defects

Antidepressants, Birth Defects, Business, Lawsuits, Pregnancies, Selective Serotonin Reuptake Inhibitors (SSRIs)

Pfizer defeated an effort to revive 300+ lawsuits alleging that its antidepressant Zoloft causes cardiac birth defects in children when taken by women during early pregnancy.